Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the 2025 European Hematology Association (EHA) Annual Meeting

Arvinas (ARVN) announced new preclinical data for its investigational oral PROTAC BCL6 degrader, ARV-393, to be presented at the European Hematology Association (EHA) meeting. The data showcases ARV-393's efficacy as a single agent in models of specific lymphomas and in combination with small molecule inhibitors in models of diffuse large B-cell lymphoma, suggesting potential for addressing previously undruggable BCL6 protein, a key driver in B-cell lymphomas. ARV-393 is currently in Phase 1 clinical trials for relapsed/refractory non-Hodgkin lymphoma.

Analysis

Arvinas, Inc. (Nasdaq: ARVN) has announced the forthcoming presentation of new preclinical data for ARV-393, its investigational oral PROTAC BCL6 degrader, at the European Hematology Association (EHA) meeting scheduled for June 12-15, 2025. The data reportedly demonstrates ARV-393's efficacy as a single agent in models of nodal T-follicular helper cell lymphoma, angioimmunoblastic-type lymphoma (AITL), and transformed follicular lymphoma, and in combination with small molecule inhibitors in diffuse large B-cell lymphoma models. This development is significant as ARV-393 targets B-cell lymphoma 6 protein (BCL6), a key transcriptional repressor and driver of B-cell lymphomas that has traditionally been considered undruggable, a challenge Arvinas' PROTAC platform aims to address. ARV-393 is currently advancing through a Phase 1 clinical trial in patients with relapsed/refractory non-Hodgkin lymphoma. The announcement is viewed with "mildly positive" sentiment (overall sentiment score 0.4, ARVN-specific 0.6) and an "optimistic" tone, suggesting the potential for ARV-393, though the market impact score of 0.35 indicates this specific news is not expected to be a major short-term catalyst. Arvinas is also progressing other investigational drugs, including vepdegestrant and ARV-102, underscoring its commitment to its protein degradation platform, though the company's forward-looking statements appropriately highlight the substantial risks and uncertainties inherent in clinical development.

Key Decisions for Investors

• Investors should closely monitor the upcoming EHA presentation and subsequent data readouts from ARV-393's Phase 1 clinical trial, as these will be crucial for validating its therapeutic potential and safety.
• While the preclinical efficacy of ARV-393 in targeting the previously 'undruggable' BCL6 is encouraging, the early stage of development necessitates a cautious approach, aligning investment with risk tolerance for clinical-stage biotechnology assets.
• Evaluate Arvinas not solely on ARV-393, but also consider the progress and potential of its broader PROTAC platform and other pipeline candidates like vepdegestrant and ARV-102, as these contribute to the company's long-term risk-reward profile.